Wolfgang Miesbach: Translating Gene Therapy into Haemophilia Care at EHA 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Honoured to be speaking at EHA 2026 this Friday, 12 June in the ‘Gene engineering and therapy’ session.
In ‘Translating Genetic Innovation into Haemophilia Care’ (P141-2), I’ll explore how three decades of gene therapy development are reshaping not just treatment, but how care itself is organised — from the structure of treatment centres to the way we follow patients across their lifetimes.
Haemophilia has long been a proving ground for genetic medicine, and the lessons here ripple out to many other conditions.
I’ll also reflect on a sobering reality: some gene therapies are being pulled from the market not because they failed patients, but because the business model did.
The future of genetic medicine may depend less on what we can cure than on what our systems are willing to pay for.”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 14, 2026, 16:35Sultan Aydın Aslantaş: A Rare Coexistence of LAHPS and Bloom Syndrome in a Child
-
Nov 14, 2026, 16:27Nicolas Moniotte: Dual-Platform Gene Editing for Haemophilia A
-
Nov 14, 2026, 15:30Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia – EHA
-
Nov 14, 2026, 15:07Vaidehi Prasanth: Patient Blood Management in Hematological Patients A New Book Chapter
-
Nov 14, 2026, 15:00Ram Mohan Jaiswal: International Collaboration in Transfusion Medicine Through the Trans Med Africa Consortium
-
Nov 14, 2026, 14:48Jamie Sin Ying Ho: Stopping Anticoagulation After AF Ablation and Rhythm Control
-
Nov 14, 2026, 14:29Satya Prakash: Cell-Free Hemoglobin-Based Oxygen Carriers and Their Clinical Development
-
Nov 14, 2026, 14:24Adela Castro: Distinguishing Antiphospholipid Antibodies From APS in Pregnancy
-
Nov 14, 2026, 14:20Uzima Chirwa: Rethinking Comprehensive Care for Bleeding Disorders in Africa